ADVA
20.5.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has upgraded its complete portfolio of Oscilloquartz PTP grandmaster clocks, enabling power utilities to smoothly transition to packet network synchronization. The enhanced technology will empower electricity providers to evolve their infrastructure into smart grids based on Precision Time Protocol (PTP) power profiles, while at the same time supporting all legacy timing signals. Updates to ADVA’s Oscilloquartz pluggable solution, its compact small cell device, its mid-size PTP grandmasters and its fully redundant core timing technology ensure ultra-precise timing throughout the utility network. What’s more, the technology removes the risk of relying purely on satellite-based time sources through continuous monitoring, jamming and spoofing detection and AI-assisted analytics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005048/en/
“Our upgraded technology makes it simple to modernize utility infrastructure. Now, power network operators can achieve the accurate and stable synchronization needed to develop smart grid power networks built on packet-based solutions, while also maintaining legacy timing,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Our technology provides a clear and cost-efficient path to robust and future-proof utility network synchronization. Its PTP timing delivery complements and replaces legacy protocols, enabling the accurate and resilient timing needed for emerging intelligent applications. Along with our multi-constellation GNSS receivers, PTP backup is also essential for protecting critical power networks. This ensures efficient operations and the best protection from malicious attacks.”
ADVA’s entire range of Oscilloquartz grandmaster clocks has been upgraded to meet the latest PTP profiles for time, frequency and phase synchronization in power utility networks. This includes the OSA 5401 small form-factor pluggable, the OSA 5405 for indoor and outdoor substation deployments, the OSA 5420 Series, and the highly scalable OSA 5430 and 5440 with 10Gbit/s interfaces and fully redundant hardware. The technologies enable an easy migration to an Ethernet-based timing network with support for PTP, Network Time Protocol (NTP) and SyncE, as well as IRIG-B, PPS and BITS legacy interfaces. PTP-based backup combined with multi-band GNSS receivers and advanced monitoring capabilities ensure that the upgraded solutions provide highly reliable delivery of precise timing information even during long GNSS outages. And, to create an ePRTC solution, ADVA’s Oscilloquartz cesium clocks can also be combined with the OSA 5420, 5430 or 5440. This delivers extended holdover of up to 70 nanoseconds for 14 days, even when GNSS signals are unavailable.
”By optimizing our synchronization technology, we’re enabling power utilities to achieve the stringent levels of precision necessary for synchronization from the substation to the core of the smart grid network. Our comprehensive portfolio empowers utilities to complement and then replace their legacy timing protocols with PTP. What’s more, our continually evolving software supports the broadest range of interfaces and profiles, ensuring a solution ready to grow with future needs,” commented Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. ”IRIG-B and NTP have served the utility industry well. But the future is all about PTP power profiles delivering new levels of precision and reliability to substations with or without GNSS. This upgrade ensures operators can rely on extremely accurate frequency, phase and time services without the threat of outages caused by jamming and spoofing.”
Watch this video for more information: https://youtu.be/iHA_TI32T6A .
Further details are also provided in these slides: https://adva.li/power-utilities-slides .
A supporting solution sheet is available here: https://adva.li/smart-grids-solution-sheet .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005048/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom